View:
Download DOC
Download PDF
Download XLS
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

Date of Report: May 25, 2021

Commission File Number: 001-39307

Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)


2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐
Legend Biotech to Present at the Jefferies Virtual Healthcare Conference

On May 25, 2021, Legend Biotech Corporation (the “Company”) issued a press release, which is attached to this Form 6-K as Exhibit 99.1, announcing that it will present at the Jefferies Virtual Healthcare Conference on June 3, 2021 at 9:30 am ET.

EXHIBIT INDEX

Exhibit
  
Title
   
  
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
LEGEND BIOTECH CORPORATION
(Registrant)
     
May 25, 2021
By:
/s/ Ying Huang
   
Ying Huang, Ph.D.
   
Chief Executive Officer and Chief Financial Officer

Exhibit 99.1


Legend Biotech to Present at the Jefferies Virtual Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)--May 25, 2021--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced it will present at the Jefferies Virtual Healthcare Conference on June 3, 2021 at 9:30 am ET. This webcast will be available to investors and other interested parties by accessing the Legend Biotech website at https://investors.legendbiotech.com

About Legend Biotech

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 800 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need.

We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, cilta-cel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.

Contacts

For Media and Investor Relations inquiries:

Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech
jessie.yeung@legendbiotech.com or investor@legendbiotech.com

Crystal Chen, Manager of Investor Relations and Corporate Communications, Legend Biotech
crystal.chen@legendbiotech.com or media@legendbiotech.com